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Abstract
Background Oral anticoagulants (OACs) mitigate stroke risk in patients with atrial fibrillation (AF). The study aim was to
analyze prevalence and predictors of OAC underutilization.
Methods Newly diagnosed AF patients with a C
 HA2DS2-VASc score ≥ 2 were identified from the US CMS Database (January 1, 2013–December 31, 2017). Patients were stratified based on having an OAC prescription versus not and the OAC
prescription group was stratified by direct OAC (DOACs) versus warfarin. Multivariable logistic regression models were
used to examine predictors of OAC underutilization.
Results Among 1,204,507 identified AF patients, 617,611 patients (51.3%) were not prescribed an OAC during follow-up
(mean: 2.4 years), and 586,896 patients (48.7%) were prescribed an OAC during this period (DOAC: 388,629 [66.2%];
warfarin: 198,267 [33.8%]). Age ≥ 85 years (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.55–0.56), female sex (OR
0.96, 95% CI 0.95–0.96), Black race (OR 0.78, 95% CI 0.77–0.79) and comorbidities such as gastrointestinal (GI; OR 0.43,
95% CI 0.41–0.44) and intracranial bleeding (OR 0.29, 95% CI 0.28–0.31) were associated with lower utilization of OACs.
Furthermore, age ≥ 85 years (OR 0.92, 95% CI 0.91–0.94), Black race (OR 0.78, 95% CI 0.76–0.80), ischemic stroke (OR
0.77, 95% CI 0.75–0.80), GI bleeding (OR 0.73, 95% CI 0.68–0.77), and intracranial bleeding (OR 0.72, 95% CI 0.65–0.80)
predicted lower use of DOACs versus warfarin.
Conclusions Although OAC therapy prescription is the standard of care for stroke prevention in AF patients, its overall utilization is still low among Medicare patients ≥ 65 years old, with specific patient characteristics that predict underutilization.
Keywords Oral anticoagulant therapy · Elderly · Atrial Fibrillation · Direct oral anticoagulant · Underutilization
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice. The incidence of AF in the United States (US) is expected to double
from 1.2 million in 2010 to 2.6 million in 2030 largely due
to an aging population [1–3]. AF is associated with a fivefold
increased risk of stroke, and AF-related strokes are associated with worse morbidity and mortality when compared to
strokes not related to AF [4, 5].
Oral anticoagulants (OACs) are the standard of care for
mitigating stroke risks in AF patients. Due to better safety
and efficacy, direct-acting oral anticoagulants (DOACs) are
now recommended as first-line treatment compared to warfarin for reduction of stroke in AF patients based on eligible
CHA2DS2-VASc score [1, 6, 7]. Patients ≥ 65with AF are
especially prone to ischemic stroke and studies have shown
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absolute reduction in the risk of stroke in such patients
when prescribed OAC therapy [8]. Several earlier studies
have shown underutilization of OAC therapy in eligible AF
patients. However, most of these studies were done in the
era when DOACs were still investigational or assimilating
into clinical practice [9–14]. Therefore, we conducted a realworld observational study from a large sample of Medicare
patients in order to assess the prevalence and predictors of
OAC therapy underutilization among AF patients ≥ 65 years
of age at risk of stroke in contemporary practice. We also
assessed the trends of warfarin and DOAC utilization over
our study time period and the predictors of DOAC therapy
prescription (i.e., either apixaban, dabigatran, edoxaban. or
rivaroxaban) versus warfarin.

2 Methods
2.1 Data source
This was a retrospective cohort study using the United
States Centers for Medicare & Medicaid Services (CMS)
fee-for-service Medicare dataset (100%) from January 1,
2012 to December 31, 2017. Fee-for-service Medicare is a
federal health insurance program that covers over 38 million
patients, including those aged ≥ 65 years and other special
groups of patients in the US. The database contains medical
and pharmacy claims from Medicare data, including inpatient, outpatient, carrier, Part D, skilled nursing facility,
home health agency, and durable medical equipment claims.
Pharmacy claims are recorded based on the drug dispensed
using the National Drug Code coding system.

2.2 Patient selection
Patients were required to be 65 years or older and have ≥ 1
inpatient or ≥ 2 outpatient medical claims (separated
by ≥ 7 days) for AF in any diagnosis position. The first
AF diagnosis date was designated as the index date for the
purposes of our analysis. Patients were required to have a
CHA2DS2-VASc score of ≥ 2 during the 12-month pre-index
period (baseline period). This was based on previous AF
consensus guidelines which, at the time of practice, recommended OAC therapy prescriptions based on this stroke risk
scoring system [1]. In addition, patients were also required
to have continuous health plan enrollment with medical and
pharmacy benefits during the baseline period and ≥ 6 months
after the index date (follow-up period). In order to select only
patients with incident AF during the study period, patients
with an AF diagnosis prior to the index date were excluded.
Patients with medical claims indicating diagnosis of rheumatic mitral valvular heart disease and valve replacement
procedure were excluded. In addition, those with pharmacy
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claims for an OAC therapy prescription (i.e., apixaban,
dabigatran, edoxaban, rivaroxaban, or warfarin) during the
baseline period were excluded to ensure new OAC use. All
relevant International Classification of Disease, 9th/10th
revision, clinical modification [ICD-9/10-CM] diagnosis,
and procedure codes are presented in Supplemental Table 1.
Patients were assigned to the OAC-prescribed or not
OAC-prescribed cohorts based on whether they were ever
prescribed OAC therapy at any time on or after the index
AF diagnosis (follow-up period). Based on the type of index
prescription, patients were assigned to either the DOAC
(apixaban, dabigatran, edoxaban, or rivaroxaban) or warfarin sub-cohorts. Figure 1 further depicts detailed patient
selection criteria.

2.3 Baseline variables
Patient demographics, clinical characteristics (i.e., clinical
risk scores, comorbidities, and medications) and health care
utilization (emergency room [ER], office visits, and inpatient
admissions) were measured during the 12-month baseline
period. Age, sex, and race were measured on the index date.
While race is acknowledged here as a social construct, this
study assessed race categories based on CMS codes [15].
Patient CHA2DS2-VASc scores were tabulated to assess
stroke risk, while modified, code-based HAS-BLED scores
(international normalized ratio [INR], lab values, and selfreported alcohol consumption were not available) were tabulated to evaluate risk of bleeding. Evidence of bleeding and
stroke was evaluated during the 12-month baseline period.
A history of major bleeding was classified as intracranial
(ICH), major gastrointestinal (GI), or other major bleeding based on claims in the inpatient setting in the primary
diagnosis position. In addition, non-major bleeding in any
clinical setting was evaluated. A history of stroke/systemic
embolism (SE) was classified as ischemic stroke and SE
based on a primary diagnosis in the inpatient setting. Hemorrhagic stroke was not separately assessed, as it was a component of intracranial bleeding.

2.4 Statistical analysis
All variables were stratified by cohort and analyzed descriptively. Means and standard deviations were provided for continuous variables. Frequencies and percentages were provided for categorical variables. T-tests and chi-square tests
were conducted to compare cohorts.
Multivariable logistic regression models were constructed to assess the adjusted association of baseline
demographics, clinical characteristics, medications, and
health care utilization with OAC therapy prescription. All
baseline variables were included in the logistic regression
model to assess for potential independent predictors, and
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Fig. 1  Patient selection criteria. AF, atrial fibrillation; DOAC, direct oral anticoagulants; ICD-9/10-CM: International Classification of Disease
9th/10.th Revision Clinical Modification

to adjust for potential confounding (See Table 1 for complete list). Age and sex were forced into the model. Backward stepwise model selection was used with entry and
stay thresholds of p < 0.15 each to select variables. In the
main analysis, age was considered as a categorical variable
(65–74, 75–84, ≥ 85 years); however, in a supplemental
analysis, age was included in the model as a continuous
variable. The presence of interactions between selected
study variables of clinical significance were evaluated
based on a priori specification. A P value < 0.05 was considered significant for main effects, while a P value < 0.10
was considered statistically significant for interaction
terms. All analyses were conducted using SAS 9.4 [Cary,
NC]. Missing data, if any, were not imputed.

3 Results
3.1 Baseline characteristics
After application of the selection criteria, 1,204,507 AF
patients with a CHA2DS2-VASc ≥ 2 were identified. Out
of these, 617,611 (51.3%) patients were not prescribed
OAC therapy versus 586,896 (48.7%) patients who were
prescribed OAC therapy (during follow-up).
Among those prescribed an OAC, 388,629 (66.2%)
were prescribed a DOAC and 198,267 (33.8%) were prescribed warfarin. Patients who were prescribed DOACs
were younger (77.8 ± 7.2 vs. 78.2 ± 7.4 years; P < 0.0001)
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Table 1  Baseline characteristics of Medicare patients with atrial fibrillation: prescribed versus not prescribed oral anticoagulant therapy
Prescribed with OAC cohort
Prescribed with OAC cohort Not prescribed with OAC
cohort

a

Age
65–74 years
75–84 years
≥ 85 years
Sexa
Male
Female
Racea
White
Black
Other
US geographic r egiona
Northeast
Midwest
South
West
Other
Medicaid dual eligibilitya
Part-D low-income subsidy
Charlson comorbidity index scorea
CHA2DS2-VASc score
2–3
4–5
≥6
HAS-BLED scoreb
0–2
3–4
≥5
Major bleedinga
Gastrointestinal bleeding
Intracranial bleeding
Other major bleeding
Non-major bleeding a
Stroke/systemic embolism a
Ischemic stroke
Systemic embolism
Baseline comorbiditiesa
Obesity
Congestive heart failure
Diabetes
Hypertension
Chronic obstructive pulmonary disease
Renal disease
Myocardial infarction
Dyspepsia or stomach discomfort
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DOAC cohort

Warfarin cohort

N = 388,629

N = 198,267

N = 586,896

N = 617,611

N/Mean (%/SD)

N/Mean (%/SD) p-value N/mean (%/SD)

N/mean (%/SD)

p-value

77.9 (7.3)
212,736 (36.2%)
252,919 (43.1%)
121,241 (20.7%)

80.4 (8.7)
184,992 (30.0%)
219,470 (35.5%)
213,149 (34.5%)

78.2 (7.4)
68,820 (34.7%)
85,915 (43.3%)
43,532 (22.0%)

< .0001
< .0001
.0084
< .0001

263,182 (44.8%)
323,714 (55.2%)

258,047 (41.8%) < .0001 174,655 (44.9%) 88,527 (44.7%) .0340
359,564 (58.2%) < .0001 213,974 (55.1%) 109,740 (55.3%) .0340

526,355 (89.7%)
31,823 (5.4%)
28,718 (4.9%)

532,722 (86.3%) < .0001 350,403 (90.2%) 175,952 (88.7%) < .0001
47,273 (7.7%)
< .0001 18,572 (4.8%)
13,251 (6.7%)
< .0001
37,616 (6.1%)
< .0001 19,654 (5.1%)
9,064 (4.6%)
< .0001

117,328 (20.0%)
156,387 (26.6%)
216,612 (36.9%)
95,617 (16.3%)
952 (0.2%)
142,530 (24.3%)
158,342 (27.0%)
2.9 (2.6)
4.5 (1.6)
165,347 (28.2%)
269,105 (45.9%)
152,444 (26.0%)
3.3 (1.2)
173,236 (29.5%)
320,318 (54.6%)
93,342 (15.9%)

117,899 (19.1%)
148,821 (24.1%)
239,362 (38.8%)
110,357 (17.9%)
1,172 (0.2%)
213,457 (34.6%)
230,173 (37.3%)
3.4 (2.8)
4.8 (1.6)
143,759 (23.3%)
280,725 (45.5%)
193,127 (31.3%)
3.5 (1.3)
150,703 (24.4%)
336,331 (54.5%)
130,577 (21.1%)

< .0001
< .0001
< .0001
< .0001
.0003
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
.1805
< .0001

76,436 (19.7%)
91,920 (23.7%)
157,130 (40.4%)
62,579 (16.1%)
564 (0.1%)
86,619 (22.3%)
96,778 (24.9%)
2.8 (2.5)
4.4 (1.6)
117,395 (30.2%)
177,882 (45.8%)
93,352 (24.0%)
3.2 (1.2)
119,908 (30.9%)
212,710 (54.7%)
56,011 (14.4%)

40,892 (20.6%)
64,467 (32.5%)
59,482 (30.0%)
33,038 (16.7%)
388 (0.2%)
55,911 (28.2%)
61,564 (31.1%)
3.2 (2.7)
4.7 (1.6)
47,952 (24.2%)
91,223 (46.0%)
59,092 (29.8%)
3.4 (1.2)
53,328 (26.9%)
107,608 (54.3%)
37,331 (18.8%)

< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
.0829
< .0001
< .0001
< .0001
.0008
< .0001

4214 (0.7%)
1530 (0.3%)
4343 (0.7%)
116,788 (19.9%)

12,640 (2.0%)
6108 (1.0%)
12,446 (2.0%)
151,153 (24.5%)

< .0001
< .0001
< .0001
< .0001

2282 (0.6%)
862 (0.2%)
2226 (0.6%)
71,445 (18.4%)

1932 (1.0%)
668 (0.3%)
2117 (1.1%)
45,343 (22.9%)

< .0001
< .0001
< .0001
< .0001

22,139 (3.8%)
1047 (0.2%)

13,605 (2.2%)
315 (0.1%)

< .0001 12,992 (3.3%)
< .0001 404 (0.1%)

9147 (4.6%)
643 (0.3%)

< .0001
< .0001

127,003 (21.6%)
156,480 (26.7%)
226,134 (38.5%)
523,486 (89.2%)
139,003 (23.7%)
138,975 (23.7%)
77,994 (13.3%)
121,554 (20.7%)

99,037 (16.0%)
189,105 (30.6%)
244,240 (39.5%)
544,917 (88.2%)
178,607 (28.9%)
179,699 (29.1%)
98,318 (15.9%)
157,020 (25.4%)

< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001

44,081 (22.2%)
61,967 (31.3%)
82,101 (41.4%)
177,401 (89.5%)
51,062 (25.8%)
56,622 (28.6%)
31,298 (15.8%)
43,354 (21.9%)

< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001

< .0001
< .0001
< .0001
< .0001

77.8 (7.2)
143,916 (37.0%)
167,004 (43.0%)
77,709 (20.0%)

82,922 (21.3%)
94,513 (24.3%)
144,033 (37.1%)
346,085 (89.1%)
87,941 (22.6%)
82,353 (21.2%)
46,696 (12.0%)
78,200 (20.1%)
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Table 1  (continued)
Prescribed with OAC cohort
Prescribed with OAC cohort Not prescribed with OAC
cohort

Peripheral vascular disease
Transient ischemic attack
Coronary artery disease
History of falls
Baseline medication usage a
ACE/ARB
Amiodarone
Beta blockers
H2-receptor antagonist
Proton pump inhibitor
Statins
Anti-platelets
NSAIDS
Baseline all-cause health care
utilization†
Inpatient admission visit
ER visit
# of office visit (PPPM)
a
b

DOAC cohort

Warfarin cohort

N = 388,629

N = 198,267

N = 586,896

N = 617,611

N/Mean (%/SD)

N/Mean (%/SD) p-value N/mean (%/SD)

N/mean (%/SD)

p-value

274,992 (46.9%)
47,167 (8.0%)
247,242 (42.1%)
42,554 (7.3%)

333,554 (54.0%)
53,598 (8.7%)
294,580 (47.7%)
75,136 (12.2%)

< .0001
< .0001
< .0001
< .0001

173,898 (44.7%)
31,913 (8.2%)
158,793 (40.9%)
26,673 (6.9%)

101,094 (51.0%)
15,254 (7.7%)
88,449 (44.6%)
15,881 (8.0%)

< .0001
< .0001
< .0001
< .0001

348,128 (59.3%)
9044 (1.5%)
282,705 (48.2%)
38,175 (6.5%)
174,744 (29.8%)
328,330 (55.9%)
83,148 (14.2%)
142,065 (24.2%)

323,724 (52.4%)
16,909 (2.7%)
270,271 (43.8%)
51,268 (8.3%)
204,186 (33.1%)
315,799 (51.1%)
103,992 (16.8%)
136,148 (22.0%)

< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001
< .0001

232,399 (59.8%)
6118 (1.6%)
186,247 (47.9%)
24,545 (6.3%)
115,268 (29.7%)
218,810 (56.3%)
54,377 (14.0%)
97,497 (25.1%)

115,729 (58.4%)
2926 (1.5%)
96,458 (48.7%)
13,630 (6.9%)
59,476 (30.0%)
109,520 (55.2%)
28,771 (14.5%)
44,568 (22.5%)

< .0001
.0038
< .0001
< .0001
.0074
< .0001
< .0001
< .0001

298,336 (50.8%)
194,169 (33.1%)
1.2 (1.1)

351,888 (57.0%) < .0001 184,585 (47.5%) 113,751 (57.4%) < .0001
234,104 (37.9%) < .0001 125,059 (32.2%) 69,110 (34.9%) < .0001
1.2 (1.2)
< .0001 1.2 (1.1)
1.2 (1.1)
< .0001

Variables included in the multivariate logistic model
As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8

ACE angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, DOAC direct oral anticoagulants, ER emergency room,
NSAIDs nonsteroidal anti-inflammatory drugs, OAC oral anticoagulants, PPPM per patient per month, SD standard deviation

DOAC

Warfarin

100.0%
90.0%
80.0%

Proporon Treated

Fig. 2  Trends of DOAC and
warfarin prescription over time
among incident AF Fee-forService Medicare Patients with
CHA2DS2-VASc ≥ 2. AF, atrial
fibrillation; DOAC, direct oral
anticoagulants; Q1, first quarter;
Q2, second quarter; Q3, third
quarter; Q4, fourth quarter

70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%

2013 2013 2013 2013 2014 2014 2014 2014 2015 2015 2015 2015 2016 2016 2016 2016 2017 2017
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
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◂Fig. 3  Predictors of OAC prescription vs No OAC prescription. ACE/

ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary
disease; ER, emergency room; ICH, intracranial hemorrhage; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; OAC,
oral anticoagulants; SE, systemic embolism

and had lower C HA 2DS 2-VASc (4.4 ± 1.6 vs. 4.7 ± 1.6;
P < 0.0001) and HAS-BLED (3.2 ± 1.2 vs. 3.4 ± 1.2;
P < 0.0001) scores compared to patients who were prescribed warfarin (Table 1). Figure 2 shows the trend of
OAC prescription with respect to DOAC and warfarin
status for the duration of the study period. Throughout
the study period, the proportion of patients with OAC
underutilization was relatively consistent and remained
above 50% throughout the study period. Of those patients
prescribed OACs, the proportion of patients prescribed
warfarin decreased from 52.8 to 19.2%, while the proportion of patients prescribed DOACs increased from 47.2
to 80.8% in incident AF patients during our study period
(Fig. 2).

3.2 Predictors of OAC therapy prescription
The multivariable logistic regression model identified several significant predictors of OAC underutilization (Fig. 3).
Age ≥ 85 years (OR 0.55, 95% CI 0.55–0.56), female sex
(OR 0.96, 95% CI 0.95–0.96), Black race (OR 0.78, 95%
CI 0.77–0.79), and key comorbidities such as coronary
artery disease (OR 0.89, 95% CI 0.88–0.90), diabetes (OR
0.92, 95% CI 0.91–0.93), renal disease (OR 0.86, 95% CI
0.86–0.87), history of falls (OR 0.72, 95% CI 0.71–0.73),
GI bleeding (OR 0.43, 95% CI 0.41–0.44), and intracranial
bleeding (OR 0.29, 95% CI 0.28–0.31) were associated with
underutilization of OAC therapy. Additionally, patients who
were not prescribed OAC therapy were older (mean age
80.4 ± 8.7 vs 77.9 ± 7.3 years; P < 0.0001) and had higher
CHA2DS2-VASc (4.8 ± 1.6 vs 4.5 ± 1.6; P < 0.0001) and
HAS-BLED scores (3.5 ± 1.3 vs 3.3 ± 1.2; P < 0.0001) compared to those who were prescribed OAC therapy. A previous
history of major bleeding (4.7% vs 1.6%; P < 0.0001) was
more prevalent, while obesity (16.0% vs 21.6%; P < 0.0001)
was less prevalent in those patients who were not prescribed
an OAC compared to those prescribed an OAC (Table 1).
Ischemic stroke (OR 1.94, 95% CI 1.89–1.98), SE (OR: 4.70,
95% CI 4.13–5.35), obesity (OR 1.38, 95% CI 1.36–1.39),
congestive heart failure (OR 1.08, 95% CI 1.07–1.09), and
hypertension (OR 1.10, 95% CI 1.09–1.1) were associated
with higher odds of OAC prescription (Fig. 3). In a separate
model, with age as a continuous variable, older patients were
associated with a lower odds of OAC treatment (OR 0.97,
95% CI 0.97–0.97; Supplemental Table 2).

Among AF patients prescribed an OAC, additional
multivariable logistic models identified several significant
predictors of DOAC versus warfarin prescription (Fig. 4).
Characteristics that were associated with lower odds of
DOAC versus warfarin prescription included: age ≥ 85 (OR
0.92, 95% CI 0.91–0.94), Black race (OR: 0.78, 95% CI
0.76–0.80), ischemic stroke (OR 0.77, 95% CI 0.75–0.80),
GI bleeding (OR 0.73, 95% CI 0.68–0.77), intracranial
bleeding (OR 0.72, 95% CI 0.65–0.80), residence in the
Midwest region (OR 0.75, CI 0.74–0.76), and inpatient visits
(OR 0.82, CI 0.80–0.83) (Fig. 4). Transient ischemic attack
(OR 1.22, 95% CI 1.20–1.25), obesity (OR 1.07, 95% CI
1.05–1.08), and hypertension (OR 1.05, 95 CI 1.03–1.07)
had higher odds of DOAC versus warfarin prescription.
Two prespecified sub-analyses describing the interaction
of age were performed based on the overall full analysis. The
first analysis evaluated the interaction of age with 3 prespecified patient-level variables on the outcome of OAC prescription versus no OAC prescription (Supplemental Table 3).
The second analysis evaluated the interaction of age with 4
prespecified patient level variables on the outcome of DOAC
versus warfarin prescription (Supplemental Table 4). For the
first age interaction analysis, the 3 patient level variables of
ischemic stroke, SE, and falls were identified a priori based
on clinical knowledge and selected to examine effect modification of age on the association of patient level variables
with OAC prescription. The odds of an OAC prescription
significantly increased with advancing age in patients with
a history of ischemic stroke (OR for ages 65–74 1.74, 95%
CI 1.67–1.82; OR for ages 75–84 1.86 95% CI 1.79–1.93;
OR for age ≥ 85 2.22, 95% CI 2.14–2.31). Similarly, the
odds of an OAC prescription also significantly increased
with advancing age in patients with a history of SE (OR for
ages 65–74 3.13, 95% CI 2.53–3.88; OR for ages 75–84 4.24
95% CI 3.39–5.31; OR for age ≥ 85 7.61, 95% CI 6.03–9.60).
On the contrary, the odds of an OAC prescription significantly decreased with advancing age and a prior history of
falls (OR for age 65–74 0.80, 95% CI 0.78–0.82; OR for
age 75–84 0.69, 95% CI 0.68–0.71; OR for age ≥ 85 0.71,
95% CI 0.70–0.73). For the second age interaction analysis, four patient level variables of ischemic stroke, SE, ICH,
and renal disease were identified a priori based on clinical
knowledge. These were selected to analyze effect modification of age on the association of patient level variables with
DOAC versus warfarin prescription. In patients with a prior
history of ICH, the odds of a DOAC prescription significantly increased across all age groups but warfarin was still
most commonly prescribed (OR for ages 65–74 0.60, 95%
CI 0.50–0.73; OR for ages 75–84 0.69 95% CI 0.60–0.81;
OR for age ≥ 85 1.00, 95% CI 0.80–1.25). A similar trend in
DOAC prescription was also observed in patients with renal
disease, among whom the odds of a DOAC prescription significantly increased across all age groups; however, warfarin
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◂Fig. 4  Predictors of DOAC versus warfarin prescription. ACE/ARB,

angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CAD, coronary artery disease; CHF, congestive heart failure; CI,
confidence interval; COPD, chronic obstructive pulmonary disease;
ER, emergency room; ICH, intracranial hemorrhage; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oral
anticoagulants; SE, systemic embolism

was still the preferred drug (OR for ages 65–74 0.67, 95% CI
0.65–0.68; OR for ages 75–84 0.80 95% CI 0.78–0.81; OR
for age ≥ 85 0.91, 95% CI 0.89–0.94).

4 Discussion
In t his large real-world sample of Medicare
patients ≥ 65 years old with a diagnosis of AF and stroke
risk, we report several key findings. (1) The prevalence of
OAC prescription continued to be low even after the introduction of DOACs in clinical practice, as underutilization
remained common, with more than half of eligible patients
in our study who were not prescribed an OAC during followup. (2) Over our study period, the proportion of patients
prescribed warfarin reduced from 23.9 to 9.5%, and DOAC
prescription increased from 21.4 to 39.9%, becoming the
most commonly prescribed OAC. (3. Specific patient characteristics such as advanced age, female sex, Black race, and
presence of important comorbidities (i.e., coronary artery
disease, diabetes, renal disease, history of falls, and major
bleeding) were associated with underutilization of OAC
therapy. Moreover, most of the same variables predicted
lower DOAC prescription among eligible AF patients. (4)
There was an increase in odds of OAC (with preference for
DOAC) prescription in AF patients with advancing age and
history of ischemic stroke.
One of the most devastating complications of AF is
ischemic stroke, and AF-related strokes tend to have worse
mortality and morbidity when compared to strokes unrelated to AF [4, 5]. Before the introduction of DOACs, warfarin was the standard anticoagulant used to reduce stroke
risk in eligible AF patients. Warfarin is characterized by
unpredictable pharmacokinetics, extensive food and drug
interactions, and frequent need for laboratory monitoring
[16, 17]. Several earlier studies have shown underutilization of OAC therapy in eligible AF patients for stroke risk
reduction. Most of these studies were done in the era when
warfarin was still the standard of care for stroke prevention
in AF patients, and such underutilization could be related
to an unfavorable warfarin safety profile. In a systematic
review conducted by Ogilvie et al. on AF patients with a
prior history of stroke, the utilization of OAC (warfarin)
therapy was only 60% [10]. Similarly, in a study of 9706
worldwide patients with AF, Suarez et al. showed warfarin
utilization rate of 39.5% [13]. They also showed that only

28% of patients above 75 years of age were prescribed warfarin treatment. Additionally, a study of AF and congestive
heart failure patients from the American Heart Association’s
Get With the Guidelines Heart Failure program, Piccini et al.
showed median prevalence of 64.9% for warfarin treatment
(interquartile range 55.5–73.4) among eligible patients [11].
In a more contemporary analysis of AF patients insured
by private companies, Al-Khatib et al. demonstrated that
nearly one-third of such patients were not treated with an
OAC [9]. Their study period encompassed the time frame
in which DOACs were assimilated in clinical practice. Our
more contemporary study of nearly 1.2 million Medicare
patients ≥ 65 years old with AF showed a gradual trend
towards increase in DOAC prescription (which has become
the more commonly prescribed OAC) but overall prevalence
of OAC prescription continued to be below guideline-based
recommendation in our cohort of patients with elevated
stroke risk ( CHA2DS2-VASc score ≥ 2) (Fig. 2). Of note, our
findings indicated lower utilization of OACs among patients
with a higher CHA2DS2-VASc score and this may be associated with a higher burden of comorbidities in our elderly
cohort of AF patients. Additionally, advanced age (one of
the important components of CHA2DS2-VASc) increases
the propensity for mechanical falls with a subsequent significant bleeding event which may also explain the lower
utilization of OACs in our study group.
Due to the low prevalence of OAC prescription in eligible AF patients, it is imperative to assess specific patient
characteristics that are associated with OAC underutilization. In our study, advanced age (≥ 85 years), female sex,
Black race, and comorbidities such as coronary artery disease, diabetes, renal disease, history of falls, GI bleeding,
and intracranial bleeding predicted underutilization of OAC
therapy. In a study of 674,841 AF patients who met criteria
for anti-coagulation from the National Cardiovascular Data
Registry (NCDR) Pinnacle registry, Lubitz et al. [14] also
demonstrated that female sex and renal disease predicted
under-prescription of OAC therapy. In a Veterans Health
Administration study among 10,212 device-detected AF
patients stratified by length of AF episode, Perino et al. [18]
found low levels of OAC prescription overall, even among
patients with AF episodes lasting ≥ 24 h (224 of 818 patients
were prescribed an OAC after an AF episode ≥ 24 h). In
another study from the NCDR Pinnacle registry, Thompson et al. [19] showed that OACs were underutilized in
women as compared to men (56.7% vs. 61.3%, p < 0.001).
This lower utilization in women persisted at all levels of
CHA2DS2-VASc score. The etiology behind this low utilization of OAC therapy in women is unclear but could be
related to both patient and provider preference. Shantsila
et al. [20] reported that women are more likely to refuse
OAC due to bleeding concerns and lack of logistic support
required for frequent laboratory monitoring, especially if
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they are prescribed warfarin; however, other societal and
environmental factors may be at play. Indeed, our study has
shown increased odds of DOAC prescription in women compared to men (OR 1.02, 95% CI 1.01–1.03) perhaps due to
the aforementioned reason. There may be a bias on the part
of providers in applying relevant guidelines to the female
population, which has also contributed to low OAC prescription prevalence [21, 22]. Similarly, the low prevalence
of OAC prescription in patients with renal disease could
be related to perceived risk of bleeding in such patients.
In our study, patients with renal disease also have lower
odds of DOAC prescription when compared to warfarin
(OR 0.78, 95% CI 0.77–0.79). In a recent meta-analysis of
34,082 AF patients with mild to moderate chronic kidney
disease, Ha et al. [23] demonstrated no increased risk of
bleeding with DOAC utilization (relative risk [RR] for major
bleeding 0.80, 95% CI 0.61–1.04; RR for ICH 0.49, 95% CI
0.30–0.80), indicating that DOACs can be safely utilized
in such patients. Our study also showed that Black race
was associated with lower utilization of OAC and DOAC
prescription therapy. In a study conducted by Essien et al.
with 12,417 AF patients, Black patients were less likely than
White patients to receive DOAC therapy, even after controlling for various clinical and socioeconomic factors (adjusted
OR 0.63, 95% CI 0.49–0.83) [24]. Additional studies informing on clinical, demographic, and socioeconomic factors
are needed to address such disparities in Black patients.
Our study also showed lower odds of OAC prescription in
patients with coronary artery disease. This low prevalence
can be attributed to increased bleeding risk in such patients,
as they are often concomitantly prescribed anti-platelet
therapy, although recent studies have shown reduction in
bleeding risk in these patients when dual therapy (DOAC
with either aspirin or a P2Y12 inhibitor) was utilized instead
of triple therapy [25]. Additionally, earlier studies have also
demonstrated improved utilization of OAC therapy in eligible AF patients with the implementation of structured
educational programs. In a large, randomized IMPACT-AF
(a multifaceted intervention to improve treatment with oral
anticoagulants in atrial fibrillation: an international, clusterrandomized trial) study, Vinereanu et al. have demonstrated
that a multiprong educational intervention aimed at both
patients and physicians resulted in improved utilization of
OAC from 68% at baseline to approximately 80% at 1 year
of follow-up in the intervention group (OR 3.28, 95% CI
1.67–6.44) [26].
Our age interaction analysis showed increased odds of
OAC prescription in AF patients with history of ischemic
stroke with advancing age. Similarly, we also demonstrated
increased odds of DOAC prescription in AF patients with
prior history of ischemic stroke as they aged. In a study of
8932 patients, van Walraven et al. showed increased risk of
ischemic stroke with patients age (adjusted hazard ratio per
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decade of age increase 1.45, 95% CI 1.26–1.66) [6]. They
also demonstrated that as these patients get older, the absolute benefit of OAC in reducing the incidence of ischemic
stroke increases. Moreover, while clinical guidelines recommend DOACs over warfarin for certain older patients,
and uptake appears to be moving clinical practice toward
more utilization of DOACs in these groups, greater guideline
awareness and adherence may help address persistent gaps
between evidence and practice. In this context, our study
findings provide further evidence that advanced age should
not be the only contraindication in prescribing an OAC for
stroke risk mitigation; practice patterns appear to align with
these important findings.

5 Strengths and limitations
The primary strengths of this study are the large sample size,
the long follow-up period, and sufficient statistical power
necessary to assess significant predictors of OAC underutilization as well as predictors of DOAC versus warfarin
prescription. Our sample includes a nationally representative aging population, as nearly two-thirds of Americans
aged ≥ 65 years are enrolled in a fee-for-service Medicare
health plan.
This study has some limitations that should be considered
while interpreting the results. This is a retrospective observational study and thus causal inference cannot be evaluated.
The selected variables were based on ICD-9-CM diagnosis
and procedure codes, the Healthcare Common Procedure
Coding System, and National Drug Codes on billing claims.
As such, coding errors and lack of clinical accuracy may
have introduced bias in the study. In fact, early studies have
reported up to 30% false positive and inactive AF patients
when extracted from large scale registries and elimination
of such cases have shown to improve the OAC utilization
[27]. Additionally, differential follow-up of AF patients in
our cohort may have introduced selection bias, as patients
with longer follow-ups were more likely to be treated with
an OAC. In addition, the Medicare database does not include
laboratory values or self-reported data, thus outcomes and
risk assessment (such as the modified HAS-BLED score)
should be interpreted in the context of coding algorithms.
Changes in patient characteristics between diagnosis and
prescription were not accounted for in the logistic regression
models. Presence of prescription claims may not indicate
that the medication was consumed by the patient. In addition, the covariates may have been impacted by heterogeneity. More research is needed to understand the importance of
each covariate along with validation. Our study also did not
consider drug costs, access to care, formulary changes, or
physician type or preferences. In addition, the study results
may not be generalizable to the entire US population, as this
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study only observed incident AF patients from Medicare
fee-for-service data, which only includes patients ≥ 65 years
old and certain special groups of patients. Similarly, dual
Veterans Health Administration beneficiary status was not
observable in the dataset, and dual beneficiaries may have
contributed to under- or overestimation of utilization.
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